JP2006501215A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501215A5
JP2006501215A5 JP2004527226A JP2004527226A JP2006501215A5 JP 2006501215 A5 JP2006501215 A5 JP 2006501215A5 JP 2004527226 A JP2004527226 A JP 2004527226A JP 2004527226 A JP2004527226 A JP 2004527226A JP 2006501215 A5 JP2006501215 A5 JP 2006501215A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
treating
rheumatoid arthritis
osteoarthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004527226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/003613 external-priority patent/WO2004014892A1/en
Publication of JP2006501215A publication Critical patent/JP2006501215A/ja
Publication of JP2006501215A5 publication Critical patent/JP2006501215A5/ja
Pending legal-status Critical Current

Links

JP2004527226A 2002-08-13 2003-08-03 マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体 Pending JP2006501215A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40304002P 2002-08-13 2002-08-13
PCT/IB2003/003613 WO2004014892A1 (en) 2002-08-13 2003-08-03 Monocyclic derivatives as matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
JP2006501215A JP2006501215A (ja) 2006-01-12
JP2006501215A5 true JP2006501215A5 (https=) 2006-09-14

Family

ID=31715927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004527226A Pending JP2006501215A (ja) 2002-08-13 2003-08-03 マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体

Country Status (8)

Country Link
US (1) US7132424B2 (https=)
EP (1) EP1537098A1 (https=)
JP (1) JP2006501215A (https=)
AU (1) AU2003253176A1 (https=)
BR (1) BR0313459A (https=)
CA (1) CA2494014A1 (https=)
MX (1) MXPA05001603A (https=)
WO (1) WO2004014892A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1434585A1 (en) 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
EP2436676A1 (en) 2002-06-12 2012-04-04 Symphony Evolution, Inc. Human adam-10 inhibitors
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP2934539B1 (en) * 2012-12-20 2019-03-27 Merck Sharp & Dohme Corp. C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors
WO2014099788A1 (en) * 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. C5-spiro iminothiadiazine dioxides as bace inhibitors
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
PT3442972T (pt) 2016-04-15 2020-05-29 Abbvie Inc Inibidores de bromodomínio
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2019183587A1 (en) 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020154571A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
AU2024240637A1 (en) * 2023-03-21 2025-09-18 Vivozon,Inc. Double regulator for mglur5 and hdac6 and use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2650223A (en) * 1950-08-08 1953-08-25 Abbott Lab 2,5-diketopiperazines
DE1029001B (de) * 1956-06-30 1958-04-30 Basf Ag Verfahren zur Herstellung von basisch substituierten Derivaten des Pyridazinons-(3)
DE3825468A1 (de) * 1988-07-27 1990-02-01 Basf Ag 5-amino-6-pyridazonderivate, verfahren zu ihrer herstellung und sie enthaltende herbizide mittel
US5425289A (en) * 1993-10-21 1995-06-20 Snap-On Incorporated Bung tool
DE3931432A1 (de) * 1989-09-21 1991-04-04 Hoechst Ag Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen
US5260323A (en) * 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
EP0541042A1 (de) 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
PA8498701A1 (es) * 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
IL154946A0 (en) 2000-10-26 2003-10-31 Pfizer Prod Inc Pyrimidine-2,4,6-trione metalloproteinase inhibitors
BR0114913A (pt) * 2000-10-26 2003-07-01 Pfizer Prod Inc Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
EP1368323B1 (en) 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors
DOP2002000334A (es) 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
MXPA03005870A (es) * 2001-02-14 2005-02-14 Warner Lambert Co Inhibirores de benzotiadiazina de metaloproteinasas de la matriz.
EP1370562A1 (en) * 2001-02-14 2003-12-17 Warner-Lambert Company LLC Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
WO2003033478A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
EP1434585A1 (en) 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
US6700540B2 (en) * 2002-02-14 2004-03-02 Ericsson, Inc. Antennas having multiple resonant frequency bands and wireless terminals incorporating the same
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
WO2003076416A1 (en) 2002-03-08 2003-09-18 Warner-Lambert Company Llc Oxo azabicyclic compounds
US6747147B2 (en) * 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
WO2004000321A1 (en) 2002-06-25 2003-12-31 Warner-Lambert Company Llc Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Similar Documents

Publication Publication Date Title
JP2006501215A5 (https=)
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
EP2049710A4 (en) MASTER ELECTRODE AND METHOD OF MANUFACTURING THEREOF
LU92307I2 (fr) Elviégravir sous toutes ses formes comme protégéespar le brevet de base
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
EP1857425A4 (en) PIEZOELECTRIC CERAMIC COMPOSITION AND MANUFACTURING METHOD THEREFOR
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
JP2004500380A5 (https=)
FR2895406B1 (fr) Procede pour la fabrication de 2,3-dimethylbut-1-ene
JP2005532458A5 (https=)
JP2003284553A5 (https=)
EP1879013A4 (en) METHOD FOR CONSTRUCTING SELF-VULGATED DRUG ORMULATIONS
FR2854078B1 (fr) Procede de fabrication d'une composition therapeutique immuno-stimulante.
FR2894772B1 (fr) Procede d'enrichissement en dha
EP1717258A4 (en) DIHALOGENIDE, POLYMER CONNECTION AND MANUFACTURING METHOD THEREFOR
FR2890959B1 (fr) Procede de preparation d'une composition de platre.
EP1883628A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF 3,5-DIETHYL-1,2-DIHYDRO-1-PHENYL-2-PROPYLPYRIDINE
FR2890654B1 (fr) Procede de preparation d'une composition humique artificielle, et applications
FR2888843B1 (fr) Procede de preparation d'un diarylanthracene.
BRPI0410638A (pt) derivados de azitromicina
FR2885137B1 (fr) Procede de desulfuration d'essences olefiniques
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
ITRM20030442A0 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.
EP1959001A4 (en) Hydrorefining method
FR2892012B1 (fr) Procede d'epilation